MedAdvisor (MDR.AX) Aandeel Koers
MedAdvisor Koers
In de afgelopen 14 jaar liet MedAdvisor de omzet jaarlijks met 77,8% groeien tot 63,00 Miljoen AUD. Bij MedAdvisor is de nettowinstmarge met -95,6% ten opzichte van -34,6% enkele jaren geleden gedaald.
MedAdvisor aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
MedAdvisor bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over MedAdvisor
The business model of Medadvisor Ltd revolves around providing digital health solutions and medication management services. Medadvisor operates a cloud-based platform that aims to empower patients, pharmacies, and healthcare providers with tools to enhance medication adherence and improve health outcomes. Through its mobile app and web-based portal, Medadvisor offers features such as medication reminders, prescription management, health record access, and medication ordering. The company generates revenue through subscription fees paid by pharmacies and healthcare providers, as well as transactional fees from medication orders. Medadvisor aims to transform the healthcare industry by leveraging technology to streamline medication management and enhance patient engagement.
Medadvisor Ltd primarily operates in the healthcare industry. As a leading digital medication management company, Medadvisor provides innovative solutions to improve medication adherence and patient engagement. With its advanced platform, Medadvisor integrates with various pharmacies, healthcare providers, and pharmaceutical companies to simplify medication management for individuals. By leveraging technology, Medadvisor aims to enhance patient outcomes, streamline workflows, and promote efficient healthcare delivery. With its strong presence in the healthcare sector, Medadvisor is committed to revolutionizing the way medication is managed and improving the overall patient experience.
The main competitors of Medadvisor Ltd in the market are various companies that provide similar services in the healthcare technology sector. Some notable competitors include Fred IT, Mediserve, and DoseMe. These companies also offer innovative solutions and platforms to enhance patient medication management and improve overall healthcare outcomes. Medadvisor Ltd faces stiff competition in the market, but its strong track record, extensive customer base, and continuous product development strategies position it as a leading player in the healthcare technology industry.
MedAdvisor Ltd is a leading digital medication management company based in Australia. Established in 2010, MedAdvisor has rapidly grown to become a trusted platform for individuals and healthcare providers to manage medications. The company's innovative applications offer features such as prescription management, medication reminders, and real-time adherence monitoring. MedAdvisor also collaborates with pharmacies and pharmaceutical manufacturers to enhance medication adherence and health outcomes. With a focus on patient-centric solutions, MedAdvisor aims to streamline medication management and empower individuals in making informed decisions about their healthcare. MedAdvisor Ltd continues to expand its reach and influence in the healthcare industry, delivering essential digital solutions for improved medication adherence.
Medadvisor Ltd has achieved several significant milestones. The company successfully listed on the Australian Securities Exchange (ASX) in 2015, marking a major achievement in its corporate journey. In 2016, Medadvisor launched an innovative medication adherence platform, which has revolutionized the way patients manage their prescriptions and health. The company has rapidly expanded its user base, reaching over 3 million users in 2021. Medadvisor has also formed strategic partnerships with leading pharmacy groups and healthcare providers, enhancing its market presence and credibility. Additionally, Medadvisor has consistently demonstrated strong revenue growth and continuous technological advancements, solidifying its position as a prominent player in the healthcare technology sector.
Medadvisor Ltd is primarily present in Australia.
Medadvisor Ltd represents the values of innovation, efficiency, and patient-centered care. Their corporate philosophy is centered around leveraging technology to improve medication adherence and patient outcomes. With a focus on providing convenient and accessible healthcare solutions, Medadvisor aims to empower individuals to take control of their health and medication management. Through their user-friendly platform and comprehensive medication management system, Medadvisor strives to simplify and enhance the patient experience. By integrating various healthcare partners, Medadvisor promotes collaboration and seamless communication among healthcare professionals, patients, and pharmacies. Through their commitment to advancing healthcare solutions, Medadvisor Ltd is dedicated to improving overall patient well-being.
8 analisten beoordelen het aandeel MedAdvisor momenteel: 0 adviseren kopen, 4 houden en 4 verkopen. Voor 2026 verwachten analisten dat MedAdvisor een omzet van 110,67 Miljoen AUD en winst per aandeel van 0,00 AUD behaalt.
Omgezet tegen de huidige wisselkoers noteert het aandeel MedAdvisor op 0,01 EUR (0,02 AUD).
Medadvisor Ltd is an Australian company specializing in digital medication management and patient support in adhering to medication plans. Their business model includes a patient app, a software solution for medical professionals, and a drug database. The Medadvisor app allows patients to manage their medications easily and sends reminders for dosages and times. It also informs users of potential medication interactions and health risks. The company provides medical professionals with a tool to monitor patient compliance with medication prescriptions. The drug database offers detailed information on medications, including ingredients, uses, dosages, and applications. Medadvisor works closely with hospitals, pharmacies, and drug manufacturers to enhance patient and professional networking. Overall, Medadvisor offers a practical solution for patients, professionals, and drug manufacturers using modern technology and strict data privacy standards.
De verwachte omzet van MedAdvisor bedraagt 110,67 Miljoen AUD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De verwachte winst van MedAdvisor bedraagt 282.782,02 AUD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van MedAdvisor bedraagt momenteel 38,00. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het MedAdvisor-aandeel in te schatten.
De koers-omzetverhouding (P/S) van MedAdvisor bedraagt momenteel 0,10. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het MedAdvisor-aandeel.
De Eulerpool Kwaliteitsscore voor MedAdvisor is 3/10.
De ISIN van MedAdvisor is AU000000MDR6. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
Het tickersymbool van MedAdvisor is MDR.AX. Onder dit beurstickersymbool wordt het MedAdvisor-aandeel op de beurs verhandeld.
MedAdvisor aandeel
MedAdvisor Peer Group
MedAdvisor FIGI
Alle fundamentals en diepgaande analyse van MedAdvisor
Onze aandelenanalyse van het MedAdvisor-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van MedAdvisor. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: